Physician profile
Isaac Reich
NPI 1700016797
$4,629.27
in general payments reported to CMS, 2019-2025
22 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $136 · 2021: $586 · 2022: $696 · 2023: $925 · 2024: $765 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $819.35 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $653.72 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $479.65 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $448.80 | 2019-2021 | |
| Harrow Eye, LLC | $201.55 | 2024-2025 | Vevye |
| Alcon Vision LLC | $200.19 | 2022-2025 | Rocklatan, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $181.75 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $179.37 | 2022-2023 | Tepezza, Uplizna |
| Abbvie INC. | $177.70 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $162.65 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $153.62 | 2023-2025 | Cequa |
| Dompe US, INC. | $150.26 | 2024-2025 | Oxervate |
| Amgen INC. | $146.66 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $135.30 | 2023-2025 | Xiidra, Envista Mx60 Iol, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $127.51 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $101.71 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $97.50 | 2020-2021 | |
| Astellas Pharma US INC | $92.46 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.35 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $18.65 | 2022 | |
| Akorn Operating Company LLC | $18.28 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Reich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.